NasdaqCM - Nasdaq Real Time Price USD

Avalo Therapeutics, Inc. (AVTX)

11.51 -1.59 (-12.14%)
At close: May 28 at 4:00 PM EDT
11.50 -0.01 (-0.09%)
After hours: May 28 at 6:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,449.00
1,924.00
18,051.00
5,398.00
6,699.00
--
Cost of Revenue
653.00
1,284.00
3,434.00
1,491.00
300.00
--
Gross Profit
796.00
640.00
14,617.00
3,907.00
6,399.00
--
Operating Expense
20,677.00
24,084.00
52,057.00
86,041.00
53,693.00
--
Operating Income
-19,881.00
-23,444.00
-37,440.00
-82,134.00
-47,294.00
--
Net Non Operating Interest Income Expense
-2,368.00
-3,417.00
-4,170.00
-2,391.00
49.00
--
Other Income Expense
-120,617.00
-4,669.00
-20.00
-20.00
-19,932.00
--
Pretax Income
-142,866.00
-31,530.00
-41,630.00
-84,545.00
-67,177.00
--
Tax Provision
13.00
14.00
28.00
-196.00
-2,793.00
--
Net Income Common Stockholders
-142,879.00
-31,544.00
-41,658.00
-84,376.00
-57,638.00
--
Diluted NI Available to Com Stockholders
-142,879.00
-31,544.00
-41,658.00
-84,376.00
-57,638.00
--
Basic EPS
-51.00
-114.00
-1.06k
-2.39k
-2.48k
--
Diluted EPS
-51.00
-114.00
-1.06k
-2.39k
-2.48k
--
Basic Average Shares
480.36
277.73
39.20
35.30
1,283.19
--
Diluted Average Shares
480.36
277.73
39.20
35.30
1,283.19
--
Total Operating Income as Reported
--
--
--
--
--
-16,137.41
Total Expenses
21,330.00
25,368.00
55,491.00
87,532.00
53,993.00
--
Net Income from Continuing & Discontinued Operation
-142,879.00
-31,544.00
-41,658.00
-84,376.00
-63,500.00
--
Normalized Income
-70,518.40
-27,888.67
-41,658.00
-84,349.00
-44,899.36
--
Interest Income
--
--
--
--
48.87
121.33
Interest Expense
--
3,417.00
4,170.00
2,391.00
--
--
Net Interest Income
-2,368.00
-3,417.00
-4,170.00
-2,391.00
49.00
--
EBIT
-24,344.00
-28,113.00
-37,460.00
-82,154.00
-47,294.00
--
EBITDA
-24,185.00
-27,955.00
-37,294.00
-80,497.00
-45,451.00
--
Reconciled Cost of Revenue
653.00
1,126.00
3,306.00
1,382.00
198.00
--
Reconciled Depreciation
159.00
158.00
166.00
1,657.00
1,843.00
--
Net Income from Continuing Operation Net Minority Interest
-142,879.00
-31,544.00
-41,658.00
-84,349.00
-64,384.00
--
Total Unusual Items Excluding Goodwill
-120,601.00
-4,627.00
--
--
-20,341.00
--
Total Unusual Items
-120,601.00
-4,627.00
--
--
-20,341.00
--
Normalized EBITDA
96,416.00
-23,328.00
-37,294.00
-80,497.00
-25,110.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-48,240.40
-971.67
--
--
-856.36
--
12/31/2019 - 10/14/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KTRA Kintara Therapeutics, Inc.
0.1879
+11.85%
 
ABVC ABVC BioPharma, Inc.
0.9251
-1.06%
 
ZVSA ZyVersa Therapeutics, Inc.
4.2536
-2.89%
 
TPST Tempest Therapeutics, Inc.
3.2000
-1.39%
 
CADL Candel Therapeutics, Inc.
8.55
+9.62%
 
SPRC SciSparc Ltd.
1.1000
-3.51%
 
TCBP TC Biopharm (Holdings) Plc
1.1400
+0.88%
 
CYTO Altamira Therapeutics Ltd.
1.6100
-9.55%
 
PALI Palisade Bio, Inc.
4.7600
-3.05%
 
PXMD PaxMedica, Inc.
0.3400
+8.56%